Real-World Data for Axi-Cel in Broader DLBCL Population

Brian T. Hill, MD, PhD, discusses data from a retrospective trial looking at the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with diffuse large B-cell lymphoma.

Brian Hill, MD, PhD, a physician at the Cleveland Clinic, discusses data from a retrospective trial looking at the use of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with diffuse large B-cell lymphoma (DLBCL).

Multiple centers across the United States were a part of this real-world trial, Hill says. Half the patients included would not have been eligible to receive axi-cel in the original trial, the ZUMA-1 study, due to high comorbidities, low platelet counts, and other criteria.